Abstract

Nonalcoholic fatty liver disease is becoming the most common chronic liver disease in Western countries, and limited therapeutic options are available. Here we uncovered a role for intestinal hypoxia-inducible factor (HIF) in hepatic steatosis. Human-intestine biopsies from individuals with or without obesity revealed that intestinal HIF-2α signaling was positively correlated with body-mass index and hepatic toxicity. The causality of this correlation was verified in mice with an intestine-specific disruption of Hif2a, in which high-fat-diet-induced hepatic steatosis and obesity were substantially lower as compared to control mice. PT2385, a HIF-2α-specific inhibitor, had preventive and therapeutic effects on metabolic disorders that were dependent on intestine HIF-2α. Intestine HIF-2α inhibition markedly reduced intestine and serum ceramide levels. Mechanistically, intestine HIF-2α regulates ceramide metabolism mainly from the salvage pathway, by positively regulating the expression of Neu3, the gene encoding neuraminidase 3. These results suggest that intestinal HIF-2α could be a viable target for hepatic steatosis therapy.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    NAFLD-the next global epidemic. Nat. Rev. Gastroenterol. Hepatol. 10, 621 (2013).

  2. 2.

    et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142, 1592–1609 (2012).

  3. 3.

    & Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut 66, 180–190 (2017).

  4. 4.

    , & Hypoxia-inducible factors as molecular targets for liver diseases. J. Mol. Med. (Berl.) 94, 613–627 (2016).

  5. 5.

    & A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell. Biol. 12, 5447–5454 (1992).

  6. 6.

    et al. HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292, 464–468 (2001).

  7. 7.

    et al. Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 468–472 (2001).

  8. 8.

    et al. A feedback loop involving the Phd3 prolyl hydroxylase tunes the mammalian hypoxic response in vivo. Mol. Cell. Biol. 29, 5729–5741 (2009).

  9. 9.

    et al. Hypoxia-inducible transcription factor 2α promotes steatohepatitis through augmenting lipid accumulation, inflammation, and fibrosis. Hepatology 54, 472–483 (2011).

  10. 10.

    et al. HIF2α is an essential molecular brake for postprandial hepatic glucagon response independent of insulin signaling. Cell Metab. 23, 505–516 (2016).

  11. 11.

    et al. Cross-talk between hypoxia and insulin signaling through Phd3 regulates hepatic glucose and lipid metabolism and ameliorates diabetes. Nat. Med. 19, 1325–1330 (2013).

  12. 12.

    et al. A liver Hif-2α-Irs2 pathway sensitizes hepatic insulin signaling and is modulated by Vegf inhibition. Nat. Med. 19, 1331–1337 (2013).

  13. 13.

    , & An intestinal microbiota-farnesoid X receptor axis modulates metabolic disease. Gastroenterology 151, 845–859 (2016).

  14. 14.

    et al. Microbiota-dependent hepatic lipogenesis mediated by stearoyl CoA desaturase 1 (SCD1) promotes metabolic syndrome in TLR5-deficient mice. Cell Metab. 22, 983–996 (2015).

  15. 15.

    et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J. Clin. Invest. 125, 386–402 (2015).

  16. 16.

    et al. Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. Proc. Natl. Acad. Sci. USA 103, 105–110 (2006).

  17. 17.

    , , , & Role of ceramides in nonalcoholic fatty liver disease. Trends Endocrinol. Metab. 23, 365–371 (2012).

  18. 18.

    , & The sphingolipid salvage pathway in ceramide metabolism and signaling. Cell. Signal. 20, 1010–1018 (2008).

  19. 19.

    & Diacylglycerol activation of protein kinase Cɛ and hepatic insulin resistance. Cell Metab. 15, 574–584 (2012).

  20. 20.

    et al. Endothelial PAS domain protein 1 activates the inflammatory response in the intestinal epithelium to promote colitis in mice. Gastroenterology 145, 831–841 (2013).

  21. 21.

    et al. A small-molecule antagonist of HIF2α is efficacious in preclinical models of renal cell carcinoma. Cancer Res. 76, 5491–5500 (2016).

  22. 22.

    , , & Inhibition of human neuraminidase 3 (NEU3) by C9-triazole derivatives of 2,3-didehydro-N-acetyl-neuraminic acid. Bioorg. Med. Chem. Lett. 20, 7529–7533 (2010).

  23. 23.

    et al. NEU3 inhibitory effect of naringin suppresses cancer cell growth by attenuation of EGFR signaling through GM3 ganglioside accumulation. Eur. J. Pharmacol. 782, 21–29 (2016).

  24. 24.

    & Hypoxia-inducible factors: a central link between inflammation and cancer. J. Clin. Invest. 126, 3689–3698 (2016).

  25. 25.

    et al. Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function. Cell Host Microbe 17, 662–671 (2015).

  26. 26.

    et al. Depletion of butyrate-producing clostridia from the gut microbiota drives an aerobic luminal expansion of salmonella. Cell Host Microbe 19, 443–454 (2016).

  27. 27.

    , & Indole and tryptophan metabolism: endogenous and dietary routes to Ah receptor activation. Drug Metab. Dispos. 43, 1522–1535 (2015).

  28. 28.

    et al. Colonic pro-inflammatory macrophages cause insulin resistance in an intestinal Ccl2/Ccr2-dependent manner. Cell Metab. 24, 295–310 (2016).

  29. 29.

    et al. Loss of junctional adhesion molecule A promotes severe steatohepatitis in mice on a diet high in saturated fat, fructose, and cholesterol. Gastroenterology 151, 733–746 (2016).

  30. 30.

    & Role of intestinal HIF-2α in health and disease. Annu. Rev. Physiol. 78, 301–325 (2016).

  31. 31.

    , & Oxygen metabolism and barrier regulation in the intestinal mucosa. J. Clin. Invest. 126, 3680–3688 (2016).

  32. 32.

    et al. Hypoxia-inducible factor 1-dependent induction of intestinal trefoil factor protects barrier function during hypoxia. J. Exp. Med. 193, 1027–1034 (2001).

  33. 33.

    et al. Ecto-5′-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J. Clin. Invest. 110, 993–1002 (2002).

  34. 34.

    et al. Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition. Gastroenterology 134, 145–155 (2008).

  35. 35.

    et al. Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J. Clin. Invest. 114, 1098–1106 (2004).

  36. 36.

    et al. Control of creatine metabolism by HIF is an endogenous mechanism of barrier regulation in colitis. Proc. Natl. Acad. Sci. USA 110, 19820–19825 (2013).

  37. 37.

    et al. Hypoxia-inducible factor/MAZ-dependent induction of caveolin-1 regulates colon permeability through suppression of occludin, leading to hypoxia-induced inflammation. Mol. Cell. Biol. 34, 3013–3023 (2014).

  38. 38.

    et al. The hydroxylase inhibitor dimethyloxalylglycine is protective in a murine model of colitis. Gastroenterology 134, 156–165 (2008).

  39. 39.

    et al. Hypoxia-inducible factor augments experimental colitis through an MIF-dependent inflammatory signaling cascade. Gastroenterology 134, 2036–2048.e3 (2008).

  40. 40.

    & CrossTalk proposal: Intramyocellular ceramide accumulation does modulate insulin resistance. J. Physiol. (Lond.) 594, 3167–3170 (2016).

  41. 41.

    & A ceramide-centric view of insulin resistance. Cell Metab. 15, 585–594 (2012).

  42. 42.

    et al. Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. J. Lipid Res. 56, 722–736 (2015).

  43. 43.

    et al. Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes 58, 337–343 (2009).

  44. 44.

    & Ceramides—lipotoxic inducers of metabolic disorders. Trends Endocrinol. Metab. 26, 538–550 (2015).

  45. 45.

    et al. Targeted induction of ceramide degradation leads to improved systemic metabolism and reduced hepatic steatosis. Cell Metab. 22, 266–278 (2015).

  46. 46.

    et al. Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance. Cell Metab. 20, 678–686 (2014).

  47. 47.

    et al. CerS2 haploinsufficiency inhibits β-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance. Cell Metab. 20, 687–695 (2014).

  48. 48.

    et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab. 5, 167–179 (2007).

  49. 49.

    et al. Adipocyte ceramides regulate subcutaneous adipose browning, inflammation, and metabolism. Cell Metab. 24, 820–834 (2016).

  50. 50.

    et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat. Commun. 6, 10166 (2015).

  51. 51.

    , , & The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 510, 84–91 (2014).

  52. 52.

    & Mechanisms for insulin resistance: common threads and missing links. Cell 148, 852–871 (2012).

  53. 53.

    , , , & Sphingolipids: key regulators of apoptosis and pivotal players in cancer drug resistance. Int. J. Mol. Sci. 15, 4356–4392 (2014).

  54. 54.

    et al. Increased hepatic expression of ganglioside-specific sialidase, NEU3, improves insulin sensitivity and glucose tolerance in mice. Metabolism 56, 420–429 (2007).

  55. 55.

    et al. NEU3 sialidase is activated under hypoxia and protects skeletal muscle cells from apoptosis through the activation of the epidermal growth factor receptor signaling pathway and the hypoxia-inducible factor (HIF)-1α. J. Biol. Chem. 288, 3153–3162 (2013).

  56. 56.

    et al. On-target efficacy of a HIF2α antagonist in preclinical kidney cancer models. Nature 539, 107–111 (2016).

  57. 57.

    et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature 539, 112–117 (2016).

  58. 58.

    , , & Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc. Natl. Acad. Sci. USA 98, 1583–1588 (2001).

  59. 59.

    et al. The hypoxia-inducible factor-C/EBPα axis controls ethanol-mediated hepcidin repression. Mol. Cell. Biol. 32, 4068–4077 (2012).

  60. 60.

    , , , & The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1α and HIF-2α. Mol. Biol. Cell 18, 4528–4542 (2007).

Download references

Acknowledgements

We thank L.G. Byrd, Y. Zhang, X. Gao, W. Liu, X. Gong, and T. Yan (National Cancer Institute) for assistance with the mouse studies, and B. Liu and X. Wu (Chinese Academy of Sciences) for help with the immunohistochemistry. This project was funded in part by the National Cancer Institute Intramural Research Program to F.J.G., grants from the National Key Research and Development Program of China (2016YFC0903100, 2016YFC0903102) to Changtao Jiang, the National Natural Science Foundation of China (31401011 and 81522007 to CT. J., and 81403007 to X.C.), National Institutes of Health grants ES022186 to A.D.P., and CA148828 and DK095201 to Y.M.S. S.K.R. was supported by NIDDK (K99DK110537). Q.W. was supported by the Peak Talent Foundation of Jiangsu Province Hospital of Chinese Medicine (Y2014RC18) and Jiangsu Government Scholarship for Overseas Studies. D.S. and J.Z. were supported by fellowships from the Chinese Scholarship Council.

Author information

Author notes

    • Changtao Jiang
    •  & Frank J Gonzalez

    These authors jointly directed this work.

Affiliations

  1. Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

    • Cen Xie
    • , Tomoki Yagai
    • , Yuhong Luo
    • , Qiong Wang
    • , Dongxue Sun
    • , Jie Zhao
    • , Kristopher W Krausz
    •  & Frank J Gonzalez
  2. Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Peking University, Beijing, China.

    • Xianyi Liang
    • , Lulu Sun
    • , Chunmei Jiang
    •  & Changtao Jiang
  3. Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing, China.

    • Xianyi Liang
    • , Lulu Sun
    • , Chunmei Jiang
    •  & Changtao Jiang
  4. Department of Internal Medicine, Key Laboratory of Environment and Genes Related to Diseases, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.

    • Tao Chen
    •  & Yue Wu
  5. Departments of Molecular & Integrative Physiology, Division of Gastroenterology, University of Michigan Medical School, Ann Arbor, Michigan, USA.

    • Sadeesh K Ramakrishnan
    • , Xiang Xue
    •  & Yatrik M Shah
  6. Department of Veterinary and Biomedical Sciences and the Center for Molecular Toxicology and Carcinogenesis, The Pennsylvania State University, University Park, Pennsylvania, USA.

    • Yuan Tian
    •  & Andrew D Patterson

Authors

  1. Search for Cen Xie in:

  2. Search for Tomoki Yagai in:

  3. Search for Yuhong Luo in:

  4. Search for Xianyi Liang in:

  5. Search for Tao Chen in:

  6. Search for Qiong Wang in:

  7. Search for Dongxue Sun in:

  8. Search for Jie Zhao in:

  9. Search for Sadeesh K Ramakrishnan in:

  10. Search for Lulu Sun in:

  11. Search for Chunmei Jiang in:

  12. Search for Xiang Xue in:

  13. Search for Yuan Tian in:

  14. Search for Kristopher W Krausz in:

  15. Search for Andrew D Patterson in:

  16. Search for Yatrik M Shah in:

  17. Search for Yue Wu in:

  18. Search for Changtao Jiang in:

  19. Search for Frank J Gonzalez in:

Contributions

C.X., T.Y., Y.L., X.L., T.C., Q.W., D.S., J.Z., S.K.R., L.S., Chunmei Jiang, X.X., Y.T., and K.W.K. performed the research and analyzed the data. C.X., A.D.P., Y.M.S., Y.W., Changtao Jiang and F.J.G. designed and supervised the research. C.X., Changtao Jiang and F.J.G. wrote the manuscript.

Competing interests

The authors declare no competing financial interests.

Corresponding authors

Correspondence to Yue Wu or Changtao Jiang or Frank J Gonzalez.

Supplementary information

PDF files

  1. 1.

    Supplementary Figures and Tables

    Supplementary Figures 1–12 and Supplementary Tables 1–3

  2. 2.

    Life Sciences Reporting Summary

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nm.4412